Your Health, We Care
Release date: 2026-01-07 17:15:08 Article From: Lucius Laos Recommended: 144
Ixazomib is part of an all-oral treatment regimen. When used in combination with lenalidomide and dexamethasone, it provides a convenient treatment option for patients with multiple myeloma experiencing their first relapse.
The price of Ixazomib produced by Lucius Pharmaceuticals (specification: 4mg*30 capsules) may fluctuate slightly due to factors such as sales channels, policies and market conditions. We fully understand your concern about drug prices and will provide accurate information based on real-time updates.
To ensure you obtain compliant drug purchase channels and the latest information, please feel free to contact our service team via the contact details on the homepage of our website. We will spare no effort to provide you with assistance.
A range of side effects may occur during Ixazomib treatment. If the symptoms are severe or persistent, be sure to inform your doctor promptly.
Common side effects include gastrointestinal reactions such as diarrhea, constipation and nausea, as well as new-onset skin rashes or exacerbation of existing ones. Some patients may experience back pain, abnormal swelling of the arms or legs, or weight gain caused by fluid retention. In addition, it may also be accompanied by ocular discomfort such as blurred vision, dry eyes or conjunctivitis (manifested as pink eye).
Please closely monitor your physical condition during medication and maintain communication with your medical team.
1. Store the medicine in its original packaging, tighten the bottle cap and keep it out of the reach of children.
2. Store at room temperature, avoid high temperature and humidity (do not place in the bathroom).
3. Do not remove the medicine from its original packaging before administration.
4. When discarding unused medicine, ensure that it cannot be accidentally taken by children, pets or others, and do not flush it down the toilet.
5. Do not leave unpackaged tablets or liquid medicines on countertops, tables or beside beds.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：3002025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
